Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus in Poor Prognosis Metastatic Kidney Cancer
NCT01888042Phase 2Terminated
- Sponsor
- Gustave Roussy
- Start
- Jul 2011
- Primary completion
- Jul 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of everolimus in metastatic renal cell carcinoma (mRCC), sponsored by Gustave Roussy. Primary endpoint: Overall Survival up to 56 months. Started Jul 2011; status: terminated.
02
Drugs
everolimus
03
Conditions
metastatic renal cell carcinoma (mRCC)
Beyond the preview
Go deeper on NCT01888042.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01888042.